Myositis treatment almost always begins with high-dose glucocorticoids, paired early on with a steroid-sparing immunosuppressant such as methotrexate or azathioprine to control inflammation while limiting the damage that long-term steroid use itself causes.1PubMed Central. Current Treatment for Myositis But myositis is not one disease, and the treatment path branches quickly depending on the subtype, the organs involved, and which autoantibodies show up in blood work. What works well for polymyositis or dermatomyositis may do nothing for inclusion body myositis, and a patient whose lungs are affected needs a different drug strategy than someone dealing mainly with muscle weakness or skin rashes.
Glucocorticoids as the Starting Point
Despite the absence of large placebo-controlled trials, glucocorticoids remain the first-line treatment for most forms of inflammatory myositis.2PubMed Central. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets The typical approach is a high initial dose of oral prednisone, tapered gradually over months as symptoms improve. For severe or rapidly worsening disease, intravenous pulses of methylprednisolone can bring inflammation under control faster and may reduce the total amount of oral steroids needed later.3PubMed. Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation
The goal is never to stay on high-dose steroids indefinitely. Glucocorticoids are effective at suppressing the immune attack on muscle tissue, but the side effects of prolonged use are serious and, ironically, include their own form of muscle weakness called steroid myopathy, which can be hard to distinguish from a flare of the underlying disease.3PubMed. Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation Osteoporosis is another well-known risk, and patients with myositis are already at elevated fracture risk from muscle weakness and reduced mobility.4PubMed Central. Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management This is why clinicians nearly always introduce a steroid-sparing agent early, often at the same time as the first dose of prednisone.
Steroid-Sparing Immunosuppressants
Methotrexate and azathioprine are the conventional first-line steroid-sparing drugs.5PubMed. Update on the pharmacological treatment of adult myositis Both work by broadly dampening immune activity, and both take weeks to months to reach full effect, which is why steroids are needed to cover the gap. Choosing between them often comes down to individual factors: methotrexate is usually avoided in people with significant liver disease or heavy alcohol use, while azathioprine may be preferred in patients who are planning pregnancy in the future (though neither is considered safe during pregnancy itself without careful specialist guidance).
When methotrexate or azathioprine does not produce an adequate response, the next tier of options includes mycophenolate mofetil, tacrolimus, cyclosporine, intravenous immunoglobulin, rituximab, and cyclophosphamide, used alone or in combinations.2PubMed Central. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets The order in which these are tried depends heavily on which organs are affected and how aggressive the disease is.
Mycophenolate Mofetil
Mycophenolate mofetil has built a strong reputation as a versatile second-line agent. In a small but widely cited series, six out of seven patients with autoimmune inflammatory myopathy showed marked improvement in both muscle strength and laboratory markers during treatment.6British Journal of Rheumatology. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy In another study of patients with recalcitrant dermatomyositis, ten out of twelve saw improvement in both skin and muscle symptoms within about four to eight weeks of starting the drug.7JAMA Dermatology. Mycophenolate Mofetil as an Effective Corticosteroid-Sparing Therapy for Recalcitrant Dermatomyositis
Mycophenolate has also shown promise in juvenile myositis. In a study of children and adolescents treated with it, the proportion achieving normal muscle strength scores rose substantially, and improvements were also seen in skin disease activity and overall disease measures.8Rheumatology. Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies The drug is generally well tolerated, with gastrointestinal upset being the most common side effect.
Intravenous Immunoglobulin
Intravenous immunoglobulin, known as IVIG, occupies a unique position in myositis treatment. It is especially valuable for patients who cannot tolerate steroids, who are not responding to conventional immunosuppressants, or whose disease is flaring acutely. The strongest evidence comes from dermatomyositis. In a landmark randomized trial published in the New England Journal of Medicine, about 79% of patients receiving IVIG met the threshold for meaningful improvement at 16 weeks, compared with 44% on placebo.9PubMed. Trial of Intravenous Immune Globulin in Dermatomyositis
Observational data reinforce these findings. In a tertiary center study, IVIG treatment led to significant improvements in muscle strength and substantial reductions in both creatine kinase levels and steroid doses. Roughly 44% of patients achieved full remission, and another quarter achieved partial remission.10PubMed. Intravenous Immunoglobulin for Inflammatory Myositis: Experience in a Tertiary Medical Center A systematic review of the literature concluded that IVIG is effective in adult polymyositis and dermatomyositis and is relatively well tolerated, making it a good option especially for refractory, rapidly progressive, or severe cases, and for patients who have contraindications to steroids.11PubMed. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review
IVIG is administered as an infusion, typically monthly, and can be continued long-term. It is expensive and sometimes in limited supply, which constrains access. Subcutaneous immunoglobulin is an alternative route that some patients find more convenient, though the evidence base for it in myositis specifically is thinner.
Rituximab and B-Cell Targeted Therapy
Rituximab, a drug that depletes a type of immune cell called B cells, has become an important option for myositis that does not respond to conventional immunosuppression. In the largest trial to date, the Rituximab in Myositis (RIM) study, about 83% of 195 patients with refractory myositis met the definition of improvement by week 44.12PubMed Central. Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy A separate prospective study of 60 patients showed an overall treatment response rate of 87% at six months, with all treatment-naive patients responding and 70% of those who had already failed other therapies also improving.12PubMed Central. Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy
One interesting finding from the RIM study is that not all autoantibody types respond equally to rituximab. Levels of anti-Jo-1 antibodies dropped significantly after treatment and correlated strongly with clinical improvement across multiple disease measures. Anti-Mi-2 levels also fell. But anti-SRP antibody levels did not change meaningfully, even though patients with those antibodies still sometimes improved clinically.13Rheumatology. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab This suggests that different autoantibodies reflect different disease mechanisms, and tracking their levels can help gauge whether rituximab is working in a given patient.
Calcineurin Inhibitors and Lung Involvement
When myositis involves the lungs, a condition known as interstitial lung disease or ILD, the treatment approach shifts. ILD can be life-threatening and is one of the most feared complications, particularly in dermatomyositis. Calcineurin inhibitors like tacrolimus and cyclosporine have shown value here, often combined with steroids. In a randomized trial comparing the two combinations, both groups showed significant improvements in lung function over a year, though tacrolimus showed a trend toward better progression-free survival (87% vs. 71% at 52 weeks, though the difference was not statistically significant).14PubMed. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial
A more recent study from a US cohort found that tacrolimus used as a first-line agent improved lung function more than the combination of mycophenolate or azathioprine, and that four out of five tacrolimus patients were able to get off supplemental oxygen within a year compared with none in the other group.15PubMed Central. Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease For patients with rapidly progressive ILD, cyclophosphamide or rituximab may be considered in addition to calcineurin inhibitors.
Why Inclusion Body Myositis Is Different
Inclusion body myositis, or IBM, is the most common inflammatory myopathy in people over 50, and it is frustratingly resistant to almost everything that works for other types of myositis. Various clinical trials targeting both the inflammatory and the degenerative pathways have failed to find an effective disease-modifying treatment.16PubMed Central. Exploring challenges in the management and treatment of inclusion body myositis Patients with IBM often show little or no response to the immunosuppressive therapies that help polymyositis and dermatomyositis.17Rheumatology. Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review
The current mainstay of IBM management is therefore supportive: close monitoring of swallowing and respiratory function, structured exercise to preserve strength as long as possible, and addressing mobility issues with aids and adaptations.16PubMed Central. Exploring challenges in the management and treatment of inclusion body myositis This can be demoralizing for patients who understandably want a medication that will halt or reverse the disease, and the search for effective IBM treatments is an active and urgent area of research.
Exercise as Medicine
For years, there was concern that exercise might worsen muscle inflammation in myositis. That fear has been firmly put to rest. Studies across all types and stages of myositis have confirmed that exercise is safe, and the evidence is strong enough that exercise is now considered a treatment in its own right, not merely a rehabilitation add-on.18PubMed Central. Exercise in Myositis
The benefits are especially striking in IBM, where medication options are so limited. Blood-flow restricted resistance training, a technique that uses a cuff to partially restrict blood flow during low-load exercise, was effective at maintaining quadriceps strength in IBM patients compared to a non-exercising control group, which lost an average of about 9% of quadriceps strength over just three months.18PubMed Central. Exercise in Myositis For polymyositis and dermatomyositis, exercise combined with creatine supplementation (a loading dose followed by a lower maintenance dose) improved high-intensity functional performance over six months.19PubMed Central. Nutritional interventions and dietary supplements in muscle diseases: a systematic review
A systematic review also confirmed that exercise training can help reduce fatigue and pain, two symptoms that heavily affect quality of life in myositis.20PubMed. Effect of exercise training on fatigue and pain in patients with systemic autoimmune myopathies: A systematic review The type, intensity, and supervision level of exercise should be tailored to each person’s current capacity, but the overarching message from the research is clear: staying active is better than resting.
Managing Skin Symptoms in Dermatomyositis
Dermatomyositis often involves painful, itchy, and photosensitive rashes that can persist even when muscle inflammation is under control. Treating the skin component requires attention beyond systemic immunosuppressants. Photoprotection is fundamental: broad-spectrum sunscreen, sun-protective clothing, and avoidance of prolonged sun exposure. Antimalarial drugs such as hydroxychloroquine play an important role in managing the skin involvement, though responses vary and some patients with dermatomyositis can paradoxically develop worsening skin reactions on hydroxychloroquine.21PubMed. Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review
For skin disease that does not respond to these measures, IVIG and mycophenolate mofetil are both options with supporting evidence, as discussed earlier. Topical calcineurin inhibitors and topical corticosteroids can also help localized skin lesions. Some patients have skin-predominant disease with little or no muscle involvement, a form sometimes called amyopathic dermatomyositis, and their treatment often focuses primarily on these dermatologic approaches rather than systemic immunosuppression.
When Swallowing Becomes Difficult
Dysphagia, or difficulty swallowing, is an underappreciated complication of myositis that affects quality of life and carries real safety risks including aspiration pneumonia. It is most common and most severe in IBM, but it also occurs in polymyositis and dermatomyositis. In a study of 62 patients with myositis and dysphagia, interventional procedures were performed in about 39% of them and were most frequently needed in those with IBM.22Mayo Clinic Proceedings. Dysphagia in Inflammatory Myopathy: Clinical Characteristics, Treatment Strategies, and Outcome in 62 Patients
Among the interventions, cricopharyngeal myotomy, a minor surgical procedure that cuts the muscle at the top of the esophagus to make it easier for food to pass, was the most beneficial. In a focused study of IBM patients with dysphagia, 63% of those who underwent cricopharyngeal myotomy experienced symptomatic improvement. Pharyngoesophageal dilation helped about a third of patients. A swallowing exercise called the Mendelsohn maneuver also appeared helpful in maintaining oral intake for some patients, though its benefits are harder to quantify in studies.23American Journal of Physical Medicine & Rehabilitation. Dysphagia in Inclusion Body Myositis: Clinical Features, Management, and Clinical Outcome In severe cases, a feeding tube may be necessary.
Autoantibodies and Personalized Treatment
One of the most meaningful shifts in myositis care over the past decade is the use of myositis-specific autoantibodies to guide treatment decisions. These antibodies, detected through blood tests, do more than just confirm a diagnosis. Different autoantibody profiles are associated with distinct clinical patterns, complication risks, and responses to specific drugs.24PubMed Central. Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis For example, anti-Jo-1 antibodies are associated with a syndrome that includes lung disease and arthritis, and patients with these antibodies tend to respond well to rituximab, with antibody levels tracking closely with clinical improvement.13Rheumatology. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab
The emerging picture is that each autoantibody may reflect the activation of a specific disease-driving pathway, and that targeting the right pathway with the right drug could dramatically improve outcomes.25Annals of Clinical Neurophysiology. Diagnostic and prognostic significance of myositis-specific autoantibodies in idiopathic inflammatory myopathies One study found that patients with the dermatomyositis subtype and those with muscle bundle atrophy on biopsy were more likely to fail conventional treatment, suggesting these patients might benefit from more aggressive therapy from the start.26PubMed Central. Predictive models for non-response to conventional treatment in polymyositis and dermatomyositis Autoantibody testing is not yet universally standardized, and access varies by region, but when available it adds genuine value to treatment planning.
JAK Inhibitors and the Treatment Pipeline
Among the most exciting developments in myositis treatment are Janus kinase (JAK) inhibitors, a class of drugs already used in rheumatoid arthritis and other inflammatory conditions. A systematic review of their use in dermatomyositis found that JAK inhibitors significantly improved or resolved symptoms across patients with skin disease, muscle disease, and even interstitial lung disease.27PubMed Central. Use of JAK Inhibitors in Dermatomyositis: A Systematic Literature Review The first prospective trial, using tofacitinib in ten patients with refractory dermatomyositis, demonstrated strong clinical efficacy as measured by validated myositis response criteria.28PubMed Central. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients
These are still early days. The tofacitinib trial was small and open-label, meaning there was no placebo group for comparison. Larger randomized trials are needed, and they are underway. But for patients whose dermatomyositis has resisted multiple therapies, JAK inhibitors represent a genuinely new mechanism of action. Other investigational approaches under study include drugs targeting specific cytokine pathways, complement inhibitors, and cell-based therapies, though most of these are still in preclinical or early-phase clinical testing.
Fatigue, Assistive Devices, and Daily Life
Myositis treatment conversations tend to center on muscle strength and lab values, but the symptoms that most affect day-to-day life often fly under the clinical radar. Fatigue is extremely common in myositis and tracks closely with disease activity. A large study confirmed that fatigue improves when disease activity improves, supporting the idea that it is a core feature of active disease rather than just a secondary complaint.29PubMed. Fatigue is common in myositis and is associated with disease activity If your treatment is bringing muscle enzymes down but your fatigue is not improving, that is worth flagging with your doctor as a possible sign of ongoing disease activity or a treatment side effect.
Assistive technology also deserves more attention than it typically gets. A survey of people with myositis in Australia found that use of assistive devices is high and that most users find them genuinely helpful. However, the study also identified gaps: many patients had limited access to occupational therapy input for recommendations and were unaware of potential funding options for devices.30PubMed. Consumer-driven evaluation of assistive technology usage and perceived value in people with myositis in Australia Simple aids like grab bars, raised toilet seats, jar openers, and adaptive utensils can make a meaningful difference in independence and safety, particularly for people with proximal weakness affecting the hips and shoulders.
Diet and Supplementation
Nutritional interventions are not a replacement for immunosuppressive therapy, but there is growing interest in whether diet can help modulate disease activity. A scoping review found that a Mediterranean-style diet and its key components, particularly omega-3 fatty acids, vitamin D, and antioxidants, play a role in the dietary treatment of autoimmune connective tissue diseases and warrant further exploration specifically in myositis.31PubMed. Nutritional interventions as modulators of the disease activity for idiopathic inflammatory myopathies: a scoping review Creatine supplementation combined with exercise has the most direct evidence, as noted earlier. Beyond these, maintaining adequate protein intake matters for anyone trying to rebuild or preserve muscle mass, and vitamin D is worth monitoring given both its role in immune function and the bone-health risks that come with long-term steroid use.
The evidence here is still thin enough that no specific dietary protocol can be recommended as standard care. But an anti-inflammatory dietary pattern is unlikely to cause harm and aligns with the general health advice that most rheumatologists already give their patients. If you are considering high-dose supplements, discuss them with your treatment team, as some can interact with immunosuppressive medications.